nPharmakon LLC
A company developing small molecule drugs for dermatology
Monday, September 10, 2012
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
About
|
nPharmakon is a biotech company founded in 2008 and dedicated to the discovery and development of small molecule drugs. All of nPharmakon's candidate drugs and lead compounds were identified by the company using its proprietary drug discovery technology. nPharmakon's core in-house capabilities are chemoinformatics, bioinformatics, and chemical genomics. Wet-lab capabilities are supplied by a network of contract service providers. Thus far the Company has been funded by founders and angel investors."
nPharmakon's most advanced program, NPH29 - a small molecule functional cosmetic for skin depigmentation - has clinical proof of concept. Skin lightening/depigmentation is a multi$billion market with a large unmet need, particularly in Asia. Cosmetic companies in Japan and other Asian countries as well as global multinationals have shown great interest in nPharmakon. It is currently exploring various options for partnering this program. NPH29 could reach the market and start generating income in three to four years. The invention of NPH29 provides proof-of-principle for the powerful potential of nPharmakon's discovery technology.
The business model of nPharmakon has two components:
1. Development of drug candidates discovered in-house; and
2. To provide discovery services to other companies using Pharmakon's proprietary discovery platform.
The Company is currently most active in developing small molecule drugs for dermatology (NPH29, NPH12). There is however also a very promising liver cancer program (NPH40). nPharmakon has recently initiated a major effort to establish partnerships with pharma and biotech companies on the use of its discovery technology.
3 Major Issues
|
-
Licensing Strategy: What is the proper point to take this research for licensing?
-
Commercialization Strategy: How long would it take for such technology to reach the market?
-
Future Development: What should be our strategy going forward for migrating to a therapeutic and then to a vaccine.
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - , will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
Slides
Audio
Video
Webcast
